Novozymes A/s

Novo Industri A/s

Henrik Mollgaard

Svend Gunnar Kaasgaard

Jan Lehmbeck

Bjorn Eggert Christensen

Mogens Wumpelmann

The present invention relates to methods for producing a polypeptide of interest by (a) cultivating a mutant of a parentcell, wherein (i) the mutant comprises a first nucleic acid sequence encoding the polypeptide and a second nucleic acid sequence comprising a modification of at least one of the genes responsible for the biosynthesis or secretion of at least one toxin, and (ii) the mutant produces less of the toxin than the parentcell when cultured under the same conditions; and (b) isolating the polypeptide from the culture medium. Also, mutants ofcells are provided, as well as methods for obtaining the mutant cells.

[object Object]

The present invention relates to methods for producing a polypeptide of interest by (a) cultivating a mutant of a parent cell, wherein (i) the mutant comprises a first nucleic acid sequence encoding the polypeptide and a second nucleic acid sequence comprising a modification of at least one of the genes responsible for the biosynthesis or secretion of at least one toxin, and (ii) the mutant produces less of the toxin than the parent cell when cultured under the same conditions; and (b) isolating the polypeptide from the culture medium. Also, mutants of cells are provided, as well as methods for obtaining the mutant cells.

Methods for producing polypeptides in aspergillus mutant cells

A method is provided for producing a polypeptide of interest by (a) cultivating a mutant of a parent Aspergillus cell, wherein (i) the mutant comprises a first nucleic acid sequence encoding the polypeptide and a second nucleic acid sequence comprising a modification of at least one of the genes responsible for the biosynthesis or secretion of at least one toxin, and (ii) the mutant produces less of the toxin than the parent Aspergillus cell when cultured under the same conditions; and (b) isolating the polypeptide from the culture medium. Also, mutants of Aspergillus cells are provided, as well as methods for obtaining the mutant cells.

Immobilized biologically active material in particle form is prepared by cross-linking with glutaraldehyde and polyazetidine. An aqueous dispersion or solution of biologically active material is partially cross-linked with glutaraldehyde, a wet pasty mass is recovered by dewatering and the mass is sub-divided into discrete particles. A polyazetidine prepolymer is added before, at the beginning or subsequent to partially cross-linking but prior to subdividing the pasty mass into particles, and the prepolymer is allowed to cross-link.

Growing community of inventors

Lyngby, Denmark

Henrik Mollgaard